{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:55:45Z","timestamp":1762430145686,"version":"build-2065373602"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-COVID-19 pulmonary fibrosis (PCPF) is a significant long-term complication in survivors of COVID-19. In this study, we aimed to identify clinical risk factors for PCPF and evaluate the impact of COVID-19\u2013related therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively studied hospitalized adults with confirmed COVID-19 across three hospitals in South Korea from 2020 to 2022. Inclusion required chest computed tomography (CT) imaging both before and after COVID-19 infection. PCPF was defined as fibrotic changes seen on follow-up CT performed at least one month after recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 5,720 hospitalized adults with COVID-19, 688 met the inclusion criteria, and 87 (12.6%) developed PCPF based on follow-up CT. In the multivariate logistic regression, pre-existing renal disease (adjusted odds ratio [aOR] 3.287; 95% confidential interval [CI]: 1.260\u20138.580;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.014), higher hemoglobin levels (aOR: 1.194; 95% CI: 1.032\u20131.387;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.018) and elevated CRP (aOR: 1.005; 95% CI: 1.001\u20131.009;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.022) were independently associated with increased risk of PCPF. Remdesivir use was significantly associated with a reduced risk of PCPF (aOR: 0.359; 95% CI: 0.176\u20130.734;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.005), whereas baricitinib use was associated with an increased risk (aOR: 5.633; 95% CI: 1.642\u201319.548;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.006).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PCPF remains a relevant sequela in COVID-19 survivors. Remdesivir and baricitinib use were associated with a reduced and increased risk of PCPF, respectively. Although adjusted for multiple confounders, residual indication bias of each treatment cannot be completely excluded. Therefore, prospective studies are needed to validate these associations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2025.1677734","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:47:42Z","timestamp":1762429662000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of COVID-19 therapeutics on the development of post-infectious lung fibrosis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yong Jun","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Eun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Ye","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hwa","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Kwang","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.arbres.2021.05.023","article-title":"Risk factors and clinical impact of fibrotic-like changes and the organizing pneumonia pattern in patients with COVID-19- and Non-COVID-19-induced acute respiratory distress syndrome.","volume":"58","author":"Barbeta","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2014 final report.","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"L625","DOI":"10.1152\/ajplung.00152.2021","article-title":"Lung-kidney interactions and their role in chronic kidney disease-associated pulmonary diseases.","volume":"322","author":"Bollenbecker","year":"2022","journal-title":"Am. J. Physiology-Lung Cell. Mol. Physiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0254258","DOI":"10.1371\/journal.pone.0254258","article-title":"Variable effects of underlying diseases on the prognosis of patients with COVID-19.","volume":"16","author":"Choi","year":"2021","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3349\/ymj.2022.0481","article-title":"Changes in expenditures of the national health insurance of Korea during the COVID-19 pandemic and the financial implications thereof.","volume":"64","author":"Choi","year":"2023","journal-title":"Yonsei Med. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1152\/ajpcell.00375.2021","article-title":"Long-term complications of COVID-19.","volume":"322","author":"Desai","year":"2022","journal-title":"Am. J. Physiology-Cell Physiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.3390\/jcm12062445","article-title":"Unraveling the underlying molecular mechanism of \u2018Silent Hypoxia\u2019 in COVID-19 patients suggests a central role for angiotensin II modulation of the AT1R-Hypoxia-Inducible factor signaling pathway.","volume":"12","author":"Devaux","year":"2023","journal-title":"J. Clin. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial.","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"101305","DOI":"10.1016\/j.eclinm.2022.101305","article-title":"Burden of Covid-19 restrictions: National, regional and global estimates.","volume":"45","author":"Fink","year":"2022","journal-title":"eClinicalMedicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"Incidence of co-infections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study.","volume":"27","author":"Garcia-Vidal","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/jpm13020286","article-title":"Lung dysfunction and chronic kidney disease: A complex network of multiple interactions.","volume":"13","author":"Gembillo","year":"2023","journal-title":"J. Pers. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/s2213-2600(20)30225-3","article-title":"Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy.","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3390\/molecules28052195","article-title":"Baricitinib attenuates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-\u03b21 signaling pathway.","volume":"28","author":"Gu","year":"2023","journal-title":"Molecules"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0000561","DOI":"10.1371\/journal.pgph.0000561","article-title":"Definitions matter: Heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis.","volume":"2","author":"Guerin","year":"2022","journal-title":"PLoS Global Public Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4046\/trd.2024.0137","article-title":"Determinants of limiting life-sustaining treatment in critically Ill COVID-19 patients: A multicenter study in Korean intensive care units.","volume":"88","author":"Heo","year":"2025","journal-title":"Tuberc. Respir. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19.","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.cmi.2020.07.016","article-title":"Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis.","volume":"26","author":"Langford","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"240006","DOI":"10.1183\/20734735.0006-2024","article-title":"Imaging in the diagnosis and management of fibrosing interstitial lung diseases.","volume":"20","author":"Lederer","year":"2024","journal-title":"Breathe"},{"key":"B19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4046\/trd.2023.0157","article-title":"Clinical manifestations and outcomes of older patients with COVID-19: A comprehensive review.","volume":"87","author":"Lee","year":"2024","journal-title":"Tuberc. Respir. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1013526","DOI":"10.3389\/fcimb.2022.1013526","article-title":"Pulmonary fibrosis in patients with COVID-19: A retrospective study.","volume":"12","author":"Li","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41392-023-01640-z","article-title":"The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID.","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Targeted Therapy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"692346","DOI":"10.3389\/fphar.2021.692346","article-title":"Protective effect of remdesivir against pulmonary fibrosis in mice.","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"16144","DOI":"10.1038\/s41598-021-95565-8","article-title":"More than 50 long-term effects of COVID-19: A systematic review and meta-analysis.","volume":"11","author":"Lopez-Leon","year":"2021","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.trsl.2021.09.001","article-title":"From ARDS to pulmonary fibrosis: The next phase of the COVID-19 pandemic?","volume":"241","author":"Michalski","year":"2022","journal-title":"Transl. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/cid\/ciae477","article-title":"Lower mortality risk associated with remdesivir + dexamethasone versus dexamethasone alone for the treatment of patients hospitalized for COVID-19.","volume":"80","author":"Mozaffari","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1513\/AnnalsATS.202008-1002OC","article-title":"Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment.","volume":"18","author":"Myall","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"210194","DOI":"10.1183\/16000617.0194-2021","article-title":"Recovering from a pandemic: Pulmonary fibrosis after SARS-CoV-2 infection.","volume":"30","author":"Mylvaganam","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijsu.2020.04.018","article-title":"The socio-economic implications of the coronavirus pandemic (COVID-19): A review.","volume":"78","author":"Nicola","year":"2020","journal-title":"Int. J. Surg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12890-016-0245-x","article-title":"From \u201ctraction bronchiectasis\u201d to honeycombing in idiopathic pulmonary fibrosis: A spectrum of bronchiolar remodeling also in radiology?","volume":"16","author":"Piciucchi","year":"2016","journal-title":"BMC Pulm Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med. Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1111\/bph.15418","article-title":"Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.","volume":"178","author":"Schloer","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3390\/pharmaceutics14091776","article-title":"The MEK1\/2 inhibitor ATR-002 (Zapnometinib) synergistically potentiates the antiviral effect of direct-acting Anti-SARS-CoV-2 drugs.","volume":"14","author":"Schreiber","year":"2022","journal-title":"Pharmaceutics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3349\/ymj.2023.0014","article-title":"Changes in the utilization of health care services by cancer patients during the COVID-19 pandemic.","volume":"64","author":"Seo","year":"2023","journal-title":"Yonsei Med. J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"107193","DOI":"10.1016\/j.ijid.2024.107193","article-title":"Impact of anti-fibrotic medications on post-COVID-19 pulmonary fibrosis: A systematic review and meta-analysis.","volume":"147","author":"Shu","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3349\/ymj.2022.63.8.790","article-title":"Clinical characteristics of patients who contracted the SARS-CoV-2 omicron variant from an outbreak in a single hospital.","volume":"63","author":"Sohn","year":"2022","journal-title":"Yonsei Med. J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-021-00726-w","article-title":"HIF-1\u03b1 promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19.","volume":"6","author":"Tian","year":"2021","journal-title":"Signal Transduct. Targeted Therapy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"761314","DOI":"10.3389\/fmed.2021.761314","article-title":"Persistence of symptoms after discharge of patients hospitalized due to COVID-19.","volume":"8","author":"Wu","year":"2021","journal-title":"Front. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"100903","DOI":"10.1016\/j.resmer.2022.100903","article-title":"Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.","volume":"81","author":"Yasuda","year":"2022","journal-title":"Respir. Med. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.4046\/trd.2022.0053","article-title":"Post\u2013Coronavirus disease 2019 pulmonary fibrosis: Wait or needs intervention.","volume":"85","author":"Yoon","year":"2022","journal-title":"Tuberc. Respir. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"L1120","DOI":"10.1152\/ajplung.00007.2009","article-title":"Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1.","volume":"297","author":"Zhou","year":"2009","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12931-025-03137-5","article-title":"Pathophysiological mechanisms of ARDS: A narrative review from molecular to organ-level perspectives.","volume":"26","author":"Zhou","year":"2025","journal-title":"Respir. Res."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1677734\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:47:43Z","timestamp":1762429663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1677734\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":41,"alternative-id":["10.3389\/fmicb.2025.1677734"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1677734","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1677734"}}